|
Country: USA
City: Chapel Hill, North Carolina
IHTC:
UNC Comprehensive Hemophilia Diagnostic and Treatment Center
932 Mary Ellen Jones Bldg, CB #7035
Chapel Hill , North Carolina 27599 USA
Tel.: 919 966 4736
Fax: 919 962 8224
Email: nigel_key@med.unc.edu
Website: www.med.unc.edu/thromb/comprehe/
Director: Nigel Key
Responsible for training: Nigel Key, Alice Ma, Paul Monahan, Herb Whinna
Fellowship logistics coordinator: Nigel Key
Year of IHTC designation: 1972
Areas of specialty: General hemophilia care; physiotherapy; pediatrics; orthopaedic surgery; laboratory diagnosis (not genetics); genetic diagnosis; psychology; nursing; social work.
DESCRIPTION OF TRAINING PROGRAM
Clinical activities: As the second largest HTC in the United States, the University of North Carolina Comprehensive Hemophilia Diagnostic and Treatment Center (UNC) has a wealth of clinical material. We provide annual care for nearly 600 patients with hemophilia, von Willebrand disease and other bleeding disorders. Three adult hematologists, two pediatric hematologists, two nurses, an orthopedist, and a hepatologist comprise the centre’s hemophilia treatment team. The centre participates in numerous clinical trials for the development of new products for the treatment of hemostatic disorders, as well as for the treatment of HIV and hepatitis C infection.
The University of North Carolina also has a strong program in thrombosis diagnosis and treatment. More than 500 patients with various thrombosis-related conditions and complications are seen yearly and the program provides excellent training in genetic diagnosis, vacular interventional radiology and Doppler ultrasound techniques. Researchers are working in a variety of areas, including the structure, function, and initiation of coagulation; inhibitors to coagulation; platelet physiology and function and gene therapy for hemophilia.
Laboratory activities/research: The John B. Graham Clinical Coagulation Laboratory as well as the UNC Hospitals Core Laboratory provide onsite testing for patients followed by our centre. There are six to seven personnel in the lab.
Multidisciplinary activities/research: The centre has a dedicated orthopedist and two physiotherapists. As part of the multidisciplinary team, there are also two nurses, one social worker, and individuals who provide genetic counselling as needed.
Additional information: The centre’s director has been active in the WFH Twinning program. Medical staff have all been active participants in WFH conferences, congresses, and global forums. The UNC Hemophilia Diagnostic and Treatment Center has participated in many international training experiences, including the WFH Twinning program and the ISTH Thrombosis/Vascular Training Centre ( TVTC) Fellowship program. The centre trains one to two fellows annually,
DESCRIPTION OF IHTC FACILITIES
Location: In the Central Piedmont region of North Carolina, Chapel Hill is a town of approximately 45,000 people, most of whom are affiliated with the university. It is neighbored by Durham, home of Duke University, Raleigh, the state’s capital, and the Research Triangle Park, a planned research park that is home to approximately 100 research and development facilities.
Climate: Rather temperate, with winter temperatures which are rarely below 25°F. However, the summers are hot and humid with temperature highs hovering around 90°F in July and August.
Accommodation (residence, meals, etc...): There are many rental accommodations available in the area, as well as accommodations with graduate students. There are a variety of local restaurants and many rental accommodations have access to kitchen facilities.
Transportation: Public transport at door.
Language: English
Financial assistance: Dependent on WFH funds.
Cost of living (per week): Costs of living are modest compared to large urban areas.
Communications tools for trainees: Computer, Internet access, telephone.
Other local support provided for trainees:May depend on a nationality (local diaspora, etc.)
RELEVANT PUBLICATIONS BY IHTC STAFF
Key, Nigel S. Inhibitors in congenital coagulation disorders. British Journal of Haematology, 127:379-381, 2004.
Monahan, Paul E., White, Gilbert C. Hemophilia gene therapy: Update. Current Opinion in Hematology, 9:430-436, 2002.
Russell, Karen E. et al. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs. Blood, 102:4393-4398, 2003.
|
